These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 6747820)

  • 21. Design and inference for 3-stage bioequivalence testing with serial sampling data.
    Yan F; Zhu H; Liu J; Jiang L; Huang X
    Pharm Stat; 2018 Sep; 17(5):458-476. PubMed ID: 29726096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro--in vivo correlation, a time scaling problem? Basic techniques for testing equivalence.
    Brockmeier D; Voegele D; von Hattingberg HM
    Arzneimittelforschung; 1983; 33(4):598-601. PubMed ID: 6683542
    [No Abstract]   [Full Text] [Related]  

  • 23. [Review and use of decision rules for bioequivalence trials].
    Nicolas P; Tod M; Petitjean O
    Therapie; 1993; 48(1):15-22. PubMed ID: 8356540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A time to speak out on bioequivalence and therapeutic equivalence.
    Dettelbach HR
    J Clin Pharmacol; 1986; 26(5):307-8. PubMed ID: 2871052
    [No Abstract]   [Full Text] [Related]  

  • 25. Generic equivalence and non-equivalence of drugs.
    Smith RN
    Lancet; 1972 Sep; 2(7776):528-30. PubMed ID: 4115582
    [No Abstract]   [Full Text] [Related]  

  • 26. Statistical aspects of comparative bioavailability trials.
    Westlake WJ
    Biometrics; 1979 Mar; 35(1):273-80. PubMed ID: 583027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A note on statistical methods for assessing therapeutic equivalence.
    Chow SC; Shao J
    Control Clin Trials; 2002 Oct; 23(5):515-20. PubMed ID: 12392865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical problems in interpreting comparative bioavailability trials.
    Westlake WJ
    Int J Clin Pharmacol Biopharm; 1975 Jun; 11(4):342-5. PubMed ID: 1099025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controversy. II: Bioequivalence as an indicator of therapeutic equivalence: modeling the theoretic influence of bioinequivalence on single-dose drug effect.
    Olson SC; Eldon MA; Toothaker RD; Ferry JJ; Colburn WA
    J Clin Pharmacol; 1987; 27(5):342-5. PubMed ID: 3693579
    [No Abstract]   [Full Text] [Related]  

  • 30. Which drugs should we be testing for bioavailability.
    Smith RN
    Br J Clin Pharmacol; 1975 Feb; 2(1):5-7. PubMed ID: 1234487
    [No Abstract]   [Full Text] [Related]  

  • 31. Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies.
    Blume HH; Midha KK
    J Pharm Sci; 1993 Nov; 82(11):1186-9. PubMed ID: 7904641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures.
    Walter-Sack I; Clanget C; Ding R; Goeggelmann C; Hinke V; Lang M; Pfeilschifter J; Tayrouz Y; Wegscheider K
    Clin Pharmacokinet; 2004; 43(14):1037-53. PubMed ID: 15530132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Harmonization of testing drugs for bioequivalence: problems and possible solutions].
    Zherdev VP; Kolyvanov GB; Litvin AA; Sariev AK
    Eksp Klin Farmakol; 2003; 66(2):60-4. PubMed ID: 12962051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A two one-sided tests procedure for assessment of individual bioequivalence.
    Liu J; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):49-61. PubMed ID: 9056588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equivalence testing with dental clinical trials.
    Burns DR; Elswick RK
    J Dent Res; 2001 Jun; 80(6):1513-7. PubMed ID: 11499504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A confirmatory strategy for therapeutic equivalence trials.
    Kieser M
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):388-90. PubMed ID: 7582393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Further considerations on model-independent bioavailability estimation.
    Hwang S; Kwan KC
    J Pharm Sci; 1980 Jan; 69(1):77-80. PubMed ID: 7354448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple testing for bioequivalence with pharmacokinetic data in 2 x 2 crossover designs.
    Chen YI; Huang CS
    Stat Med; 2009 Dec; 28(28):3567-79. PubMed ID: 19760611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
    Esinhart JD; Chinchilli VM
    J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S37-43. PubMed ID: 1601530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.